WHO Raises Warning Over Acute Scarcity of Obesity Injections
Under 10% of individuals eligible to benefit from obesity jabs including Wegovy have access to them, warns the WHO as it issues its first guidance on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for more widespread and fairer access to GLP-1 medication.
Per forecasts, more than two billion could be living with obesity by 2030 unless action is taken.
"Our latest guidance acknowledges that obesity is a chronic disease that can be treated with comprehensive and ongoing treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major obstacles to broad access to the treatments that can assist patients in reducing significant body mass, says the agency.
Weight-Loss Drug Supply Crisis
Even under the current most favorable outlook, the supply of these medications would only suffice for around 100 million people – fewer than 10% of eligible patients, per the health organization.
The advice urges nations and manufacturers to expand access, via approaches including voluntary licensing.
Exclusive production rights on a key compound – the main component of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs replicate a body's own hormone to delay gastric emptying, suppress the appetite and boost feelings of fullness so people consume fewer calories.
Individuals typically start to lose weight within a few weeks of beginning the weekly injections.
Research suggests users may see weight return a year later of discontinuing the treatment, as their typical food cravings resume.
To be carrying excess weight raises your likelihood for contracting health problems, including type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity affects people in all nations and was linked to millions of fatalities worldwide in 2024, as per the health agency.
